Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Lymphocytic Leukemia, Chronic Clinical Trials

A listing of Lymphocytic Leukemia, Chronic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (31) clinical trials

A Phase 1 clinical study for patients with childhood ALL, Acute myeloid leukemia, Preleukemia, Chronic myeloid leukemia, MYELODYSPLASTIC SYNDROME

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...


Patients are needed to participate in a clinical research study to evaluate B-cell Acute Lymphoblastic Leukemia, Acute myeloid leukemia, Chronic Myeloid Leukemia, Blast Crisis, Blastic Plasmacytoid Dendritic Cell Neoplasm

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.


A clinical trial to evaluate treatments for patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle cell lymphoma

This research study is a Phase I and Ib combination clinical trial, which aims to both evaluate the safety of an investigational drug combination and also tries to define the appropriate dose of the investigational drug to evaluate in later clinical trials. "Investigational" means that the intervention is being studied. ...


A clinical trial to evaluate treatments using Ibrutinib, BI 836826 for patients with Chronic Lymphocytic Leukemia

Intravenous BI 836826 in combination with ibrutinib in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) patients who have been pre-treated with at least one prior line of systemic therapy, and who are eligible for treatment with ibrutinib. Objectives of the trial are to determine the recommended Phase 2 dose of BI 836826, ...


A clinical trial seeking patients for a research study for the treatment of Blood disorder, Multiple Myeloma, MYELODYSPLASTIC SYNDROME, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...


A clinical trial seeking patients for a research study for the treatment of Waldenstrom's Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Lymphoma, Mixed Lymphoproliferative Disease

Background Persons may be prone to develop hematologic or lymphoproliferative cancer for a variety of reasons including: inherited predisposition of benign, premalignant, or malignant conditions; environmental exposures shared by family members; previous tumors or preneoplastic conditions; immune deficiency; or stochastic processes Investigations of individuals and families at high risk of ...

Phase N/A

A clinical trial sponsored by Sidney Kimmel Comprehensive Cancer Center for a research study for the treatment of ESSENTIAL THROMBOCYTHEMIA, Prolymphocytic Leukemia, Chronic Myeloproliferative Disorders, Plasma Cell Neoplasm, Multiple Myeloma, Polycythemia Vera, Monoclonal gammopathy, Chronic myelomonocytic leukemia, Chronic Lymphocytic Leukemia, MYELODYSPLASTIC SYNDROME, Plasma cell leukemia, Chronic myeloid leukemia, Myelosclerosis with myeloid metaplasia, Preleukemia

The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other ...


A clinical trial to evaluate treatments for patients with Chronic Myelomonocytic Leukemia in Remission, Graft-Versus-Host Disease, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Multiple Myeloma, Acute Myeloid Leukemia in Remission, Waldenstrom's Macroglobulinemia, Severe Aplastic Anemia, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Minimal Residual Disease, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...